Table 2.
Comparison of clinical and biological parameters between baseline and follow up 12 months after bariatric/metabolic surgery (n=14 unless otherwise noted).2
| Baseline | 12-month follow up | P(time) | |
|---|---|---|---|
| Weight (kg) | 131.7 ± 27.1 | 96.9 ± 18.0 | <0.001 |
| BMI (kg/m2) | 46.2 ± 7.5 | 34.0 ± 4.5 | <0.001 |
| Body Adiposity Index (%) | 47.8 ± 8.5 | 37.1 ± 5.8 | <0.001 |
| Fasting Plasma Glucose (mmol/L) | 5.7 (5.2 – 6.0) | 5.0 (4.7 – 5.3) | 0.003 |
| Fasting Plasma Insulin (μU/L) | 11.3 (9.6 – 17.5) | 4.3 (2.5 – 7.2) | <0.001 |
| HOMA-IR | 2.9 (2.1 – 4.6) | 1.0 (0.5 – 1.6) | <0.001 |
| 120 min Glucose (mmol/L, OGTT) | 6.6 (5.9 – 7.5) | 4.5 (3.8 – 5.0) | <0.001 |
| AUC Glucose (mmol/L*min, OGTT) | 1,310 (1,147 – 1,458) | 1,085 (975 – 1,138) | <0.001 |
| Insulinogenic Index (pmol/mmol) | 1.2 ± 0.6 | 1.2 ± 0.7 | 0.854 |
| Matsuda Index | 3.3 (1.9 – 4.8) | 7.4 (4.9 – 9.2) | <0.001 |
| Oral Disposition Index | 3.5 ± 1.6 | 7.8 ± 3.1 | <0.001 |
| Fasting Plasma CRP (mg/L) | 4.6 (1.7 – 6.3) | 1.5 (0.6 – 2.6) | 0.002 |
| Fasting Plasma IL-6 (pg/mL) | 1.8 (1.5 – 3.0) | 1.4 (1.2 – 2.2) | 0.183 |
| Fasting Plasma Adiponectin (pg/mL) | 4,608 (3,024 – 8,007) | 5,807 (5,095 – 8,224) | 0.003 |
| SQAT TNFα mRNA (copies/ng RNA) | 2.6 (2.2 – 3.8) | 2.8 (1.7 – 5.0) | 0.651 |
| SQAT IL-1β mRNA (copies/ng RNA) | 1.8 (1.5 – 2.3) | 2.5 (0.9 – 5.2) | 0.793 |
| SQAT IL-6 mRNA (copies/ng RNA) | 2.0 (1.3 – 2.6) | 2.1 (1.2 – 2.9) | 0.535 |
| SQAT Adiponectin mRNA (copies/ng RNA) | 2,816 (1,839 – 4,086) | 2,328 (2,073 – 2,688) | 0.069 |
| CD15+CD16+ Neutrophils (n=13): | |||
| per g SQAT | 12,019 (5,845 – 21,287) | 141,006 (92,300 – 194,407) | <0.001 |
| as % of CD45+ fraction | 5.1 (3.9 – 7.4) | 12.7 (8.6 – 38.4) | <0.001 |
| CD1c+CD11c+ Dendritic cells (n=12): | |||
| per g SQAT | 7,167 (3,722 – 11,172) | 20,976 (12,723 – 27,874) | 0.015 |
| as % of CD45+ fraction | 2.7 ± 1.1 | 1.8 ± 1.0 | 0.032 |
| CD14+CD206+ ATM (n=13): | |||
| per g SQAT | 20,948 (13,808 – 32,988) | 62,124 (20,222 – 114,951) | 0.019 |
| as % of CD45+ fraction | 10.2 ± 4.6 | 7.3 ± 4.1 | 0.092 |
| CD14+CD206+CD11c+ ATM (n=13): | |||
| per g SQAT | 7,477 (3,722 – 11,172) | 9,363 (12,723 – 27,874) | 0.116 |
| as % of CD45+ fraction | 3.8 ± 2.2 | 1.9 ± 1.2 | 0.01 |
| CD3+CD4+ T cells (n=12): | |||
| per g SQAT | 24,519 (17,567 – 48,297) | 84,178 (57,838 – 114,757) | 0.002 |
| as % of CD45+ fraction | 11.0 (8.3 – 13.7) | 9.0 (7.4 – 10.5) | 0.138 |
| CD3+CD8+ T cells (n=12): | |||
| per g SQAT | 18,116 (12,237 – 28,520) | 52,524 (32,760 – 92,953) | 0.006 |
| as % of CD45+ fraction | 7.7 (6.0 – 9.1) | 6.1 (4.3 – 6.9) | 0.08 |
| CD4+/CD8+ T cell ratio (n=12) | 1.3 (1.0 – 2.2) | 1.7 (1.5 – 1.8) | 0.441 |
2
Values are means ± standard deviation for normally distributed data or medians (25th, 75th percentiles) for non-normally distributed, log-transformed data. P-values are based repeated measures analysis of variance (ANOVA). HOMA-IR, homeostasis model assessment-insulin resistance (index); CRP, C-reactive protein; IL, interleukin; OGTT, oral glucose tolerance test; TNF, tumor necrosis factor; SQAT, subcutaneous adipose tissue; ATM, adipose tissue macrophage.